Literature DB >> 7910910

Protection against Alzheimer's disease with apoE epsilon 2.

C Talbot, C Lendon, N Craddock, S Shears, J C Morris, A Goate.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7910910     DOI： 10.1016/s0140-6736(94)92557-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  53 in total

Review 1.  Normal genetic variation, cognition, and aging.

Authors:  P M Greenwood; Raja Parasuraman
Journal:  Behav Cogn Neurosci Rev       Date:  2003-12

2.  Aggravated decrease in the activity of nucleus basalis neurons in Alzheimer's disease is apolipoprotein E-type dependent.

Authors:  A Salehi; E J Dubelaar; M Mulder; D F Swaab
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-15       Impact factor: 11.205

3.  APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.

Authors:  John C Morris; Catherine M Roe; Chengjie Xiong; Anne M Fagan; Alison M Goate; David M Holtzman; Mark A Mintun
Journal:  Ann Neurol       Date:  2010-01       Impact factor: 10.422

4.  Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease.

Authors:  Rawan Tarawneh; Gina D'Angelo; Elizabeth Macy; Chengjie Xiong; Deborah Carter; Nigel J Cairns; Anne M Fagan; Denise Head; Mark A Mintun; Jack H Ladenson; Jin-Moo Lee; John C Morris; David M Holtzman
Journal:  Ann Neurol       Date:  2011-08       Impact factor: 10.422

5.  Scopolamine-induced impairment as a potential predictor of Alzheimer's disease in individuals with Apolipoprotein E type 4 alleles.

Authors:  N Pomara; K Nolan; G Halpern
Journal:  Neurochem Res       Date:  1995-12       Impact factor: 3.996

6.  Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex.

Authors:  H Bickeböller; D Campion; A Brice; P Amouyel; D Hannequin; O Didierjean; C Penet; C Martin; J Pérez-Tur; A Michon; B Dubois; F Ledoze; C Thomas-Anterion; F Pasquier; M Puel; J F Demonet; O Moreaud; M C Babron; D Meulien; D Guez; M C Chartier-Harlin; T Frebourg; Y Agid; M Martinez; F Clerget-Darpoux
Journal:  Am J Hum Genet       Date:  1997-02       Impact factor: 11.025

7.  Role of family history for Alzheimer biomarker abnormalities in the adult children study.

Authors:  Chengjie Xiong; Catherine M Roe; Virginia Buckles; Anne Fagan; David Holtzman; David Balota; Janet Duchek; Martha Storandt; Mark Mintun; Elizabeth Grant; Abraham Z Snyder; Denise Head; Tammie L S Benzinger; Joseph Mettenburg; John Csernansky; John C Morris
Journal:  Arch Neurol       Date:  2011-10

8.  Clinical and psychological characteristics of the initial cohort of the Dominantly Inherited Alzheimer Network (DIAN).

Authors:  Martha Storandt; David A Balota; Andrew J Aschenbrenner; John C Morris
Journal:  Neuropsychology       Date:  2013-11-11       Impact factor: 3.295

9.  BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease.

Authors:  Yen Ying Lim; Jason Hassenstab; Carlos Cruchaga; Alison Goate; Anne M Fagan; Tammie L S Benzinger; Paul Maruff; Peter J Snyder; Colin L Masters; Ricardo Allegri; Jasmeer Chhatwal; Martin R Farlow; Neill R Graff-Radford; Christoph Laske; Johannes Levin; Eric McDade; John M Ringman; Martin Rossor; Stephen Salloway; Peter R Schofield; David M Holtzman; John C Morris; Randall J Bateman
Journal:  Brain       Date:  2016-08-12       Impact factor: 13.501

Review 10.  Apolipoprotein E, gender, and Alzheimer's disease: an overlooked, but potent and promising interaction.

Authors:  Leo Ungar; Andre Altmann; Michael D Greicius
Journal:  Brain Imaging Behav       Date:  2014-06       Impact factor: 3.978
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.